Podcasts about clinical oncology asco annual meeting

  • 21PODCASTS
  • 87EPISODES
  • 15mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Jun 2, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about clinical oncology asco annual meeting

Latest podcast episodes about clinical oncology asco annual meeting

Breastcancer.org Podcast
Making Sure Exercise is Part of Cancer Care

Breastcancer.org Podcast

Play Episode Listen Later Jun 2, 2025 12:21


At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Katie Schmitz chaired a session on ways to ensure that exercise is part of every cancer treatment plan. She also talked about how results of the CHALLENGE trial in colon cancer might apply to breast cancer. Listen to the episode to hear Dr. Schmitz explain: strategies doctors can use to make exercise an integral part of cancer care how people can afford and stay motivated to exercise the results of the CHALLENGE trial, which found that three years of exercise after colon cancer treatment improved disease-free survival (how long people lived without the cancer coming back) and overall survival (how long people lived whether or not the cancer came back)

exercise american society schmitz cancer care clinical oncology asco annual meeting
Breastcancer.org Podcast
Top Breast Cancer Research at ASCO 2025

Breastcancer.org Podcast

Play Episode Listen Later Jun 2, 2025 18:35


The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky discuss: The SERENA-6 trial, which found that if metastatic hormone receptor-positive, HER2-negative breast cancer develops ESR1 mutations during first hormonal therapy treatment, switching to camizestrant from an aromatase inhibitor before the cancer grows improves outcomes. Results from the DESTINY-Breast09 trial showing that the combination of Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Perjeta (chemical name: pertuzumab) is a better first treatment for metastatic HER2-positive breast cancer than the current standard of THP chemo.  The ASCENT-04/KEYNOTE-D19 trial, which found that people with metastatic, PD-L1-positive, triple-negative breast cancer fared better with the combo of Trodelvy (chemical name: sacituzumab govitecan-hziy) and Keytruda (chemical name: pembrolizumab) as a first treatment compared to people who received chemotherapy and Keytruda.

Oncology Peer Review On-The-Go
S1 Ep128: Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Oncology Peer Review On-The-Go

Play Episode Listen Later Sep 23, 2024 20:23


In a conversation with CancerNetwork®, Nader Sanai, MD discussed the current state of the glioblastoma field, highlighting ongoing research efforts to help improve outcomes among patients with this disease.  Sanai is the director of the Ivy Brain Tumor Center and J.N Harber Professor of Neurological Surgery, Francis and Dionne Najafi chair for Neurosurgical Oncology, and chief of neurological oncology at Barrow Neurological Institute. Specifically, Sanai described plans to assess treatment with niraparib (Zejula) compared with temozolomide (Temodar) in a population of patients with newly diagnosed MGMT unmethylated glioblastoma as part of the phase 3 Gliofocus study (NCT06388733).1 He contextualized the rationale for conducting this study by focusing on findings from a proof-of-concept hybrid study (NCT05076513) and detailing how they supported additional investigation into the utility of niraparib.  According to findings from this proof-of-concept study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the median overall survival (OS) was 20.3 months among patients who received niraparib in combination with radiotherapy.2 Additionally, data showed that niraparib reached drug concentrations in Gadolinium-nonenhancing newly diagnosed glioblastoma tissue exceeding those of any other evaluated PARP inhibitors; investigators identified no new safety signals after combining niraparib with radiotherapy in this population. With the Gliofocus trial, Sanai and co-investigators aim to provide a clinically meaningful quality of life benefit with niraparib-based therapy beyond a marginally valuable statistical advantage. By evaluating treatment with niraparib, investigators look to improve historical survival rates reported with standard-of-care options among patients with unmethylated disease. “What we're looking to do with this trial is set a benchmark that's clinically relevant for patients and providers. The [OS] target for the study is 18 months, which is to effectively convert [a] 12-month natural history to a natural history closer to the methylated glioblastoma population,” Sanai said. “We think that is a meaningful transformation of a difficult patient population, a significant chunk of survival time that would be beneficial to patients, providers, and caregivers. Importantly, [it may also mean] an advantage for quality of life, which is of paramount importance for this patient population.” References 1.        A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma. ClinicalTrials.gov. Updated June 24, 2024. Accessed September 16, 2024. https://tinyurl.com/y25er8p9 2.        Sanai N, Umemura Y, Margaryan T, et al. Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial. J Clin Oncol. 2024;42(suppl 16):2002. doi:10.1200/JCO.2024.42.16_suppl.2002

OBR Peer-Spectives
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree

OBR Peer-Spectives

Play Episode Listen Later Jul 8, 2024 12:23


Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical oncologist and professor of medicine at the University of California San Diego. Practice-changing data were presented in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), Dr. Patel told Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. 

OBR Peer-Spectives
What Were the Biggest Data at ASCO 2024 in Kidney Cancer?

OBR Peer-Spectives

Play Episode Listen Later Jul 5, 2024 11:41


The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. 

Oncology Data Advisor
Improving Long-Term Survivorship Care in Head and Neck Cancer With Erica Fortune, PhD

Oncology Data Advisor

Play Episode Listen Later Jun 27, 2024 11:56


At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Erica Fortune, PhD, Vice President of Research at Cancer Support Community, to discuss her team's poster entitled, “Head and Neck Cancer (HNC) Survivors: Long-Term Nutrition Impact Symptoms, Eating Problems, and Barriers to Care Impact Psychosocial Health.” In this podcast, Dr. Fortune delves further into this topic, including: Background about long-term side effects and quality-of-life impacts experienced by HNC survivors Cancer Support Community's survey designed to further investigate these challenges The results that the study found regarding nutrition, eating problems, and barriers to care that survivors experience How Cancer Support Community plans on using the survey results to improve survivorship and address psychosocial impacts experienced by long-term HNC survivors A preview of other topics that Cancer Support Community is excited to cover as a member organization of the Oncology Data Advisor Editorial Board And more!

Oncology Data Advisor
Addressing Barriers to Transplantation Accessibility With Monzr Al Malki, MD, and Richa Thakur, MD

Oncology Data Advisor

Play Episode Listen Later Jun 26, 2024 11:47


At the conclusion of this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Monzr Al Malki, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, sat down with Richa Thakur, a Palliative Care Physician and Hematology/Oncology Fellow at Zucker School of Medicine at Hofstra/Northwell Health, to discuss his oral abstract presentation entitled “Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.”

Oncology Peer Review On-The-Go
S1 Ep114: Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Oncology Peer Review On-The-Go

Play Episode Listen Later Jun 17, 2024 31:19


Following the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Neil M. Iyengar, MD, and Paolo Tarantino, MD, co-hosted a live X Space with CancerNetwork® and discussed the latest trial updates that may impact clinical practice in the breast cancer field. Iyengar is an associate attending physician at Memorial Sloan Kettering Cancer Center and a co-editor-in-chief of ONCOLOGY®. Tarantino is a clinical research fellow at Dana-Farber Cancer Institute and Harvard Medical School.  Iyengar and Tarantino discussed data regarding several trials and studies presented at the meeting. These presentations included:  ·      Phase 3 DESTINY-Breast06 Trial (NCT04494425)1 o   Investigators evaluated treatment with trastuzumab deruxtecan (T-DXd; Enhertu) compared with investigator's choice of chemotherapy among patients with hormone receptor (HR)–positive, HER2-low or HER2-ultralow metastatic breast cancer. o   The median progression-free survival (PFS) was 13.2 months with T-DXd compared with 8.1 months in patients who received chemotherapy across the HER2-low population (HR, 0.62; 95% CI, 0.51-0.74; P

The Drug Discovery World Podcast
DDW Highlights: 11 June 2024

The Drug Discovery World Podcast

Play Episode Listen Later Jun 11, 2024 13:28


The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

spotify google play american society megan thomas ddw clinical oncology asco annual meeting
Oncology Data Advisor
Early-Stage Non–Small Cell Lung Cancer: Answers to Frequently Asked Questions

Oncology Data Advisor

Play Episode Listen Later Jun 7, 2024 5:58


In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more!

Breastcancer.org Podcast
Predicting Triple-Negative Breast Cancer Risk in Young Black Women

Breastcancer.org Podcast

Play Episode Listen Later Jun 4, 2024 12:04


Black women have a higher risk of developing triple-negative breast cancer at a young age than white women. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Holly Pederson, of the Cleveland Clinic, and Dr. Elisha Hughes, of Myriad Genetics, presented their research on how a polygenic risk score can help predict the risk of early-onset triple-negative breast cancer in Black women. Listen to the episode to hear Drs. Pederson and Hughes explain: what a polygenic risk score is the results of their research how the results are being used

Breastcancer.org Podcast
Top Breast Cancer Research at ASCO 2024

Breastcancer.org Podcast

Play Episode Listen Later Jun 4, 2024 24:32


The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky explain: the DESTINY- Breast06 study on Enhertu compared to chemotherapy for metastatic hormone-receptor-positive breast cancer how circulating tumor DNA may help predict recurrence descalating treatment to reduce the risk of side effects

Stock Day Media
Trend Micro Incorporated | Innovent Biologics, Inc.

Stock Day Media

Play Episode Listen Later Jun 3, 2024 0:57


Trend Micro Incorporated ( TYO: 4704 ; TSE: 4704 ), a global cybersecurity leader, announced plans to demo a new data center solution, using NVIDIA technology, for security-conscious business and government customers harnessing the power of AI. This is just one of multiple AI security solutions being shown for the first time at COMPUTEX 2024. Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. For more information, please visit StockDayMedia.com

Melanoma Insights for Professionals
Transforming cancer care: Neoadjuvant therapy and trials in melanoma care

Melanoma Insights for Professionals

Play Episode Listen Later Jun 3, 2024 35:46


Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too. In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA's Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions. This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia. SPEAKERS A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney PUBLICATIONS Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823. FURTHER EDUCATION Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA's Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Breastcancer.org Podcast
Genetic Testing Saved My Life

Breastcancer.org Podcast

Play Episode Listen Later May 31, 2024 5:34


At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Brooklyn Olumba was part of ASCO Voices, a program that gives people in the oncology a community an opportunity to tell their stories. Her talk was entitled “Genetic Testing Saved My Life.” Listen to the episode to hear Dr. Olumba explain: how she came to have genetic testing at age 25 when she started breast cancer screening how she advises young women about screening

american society saved my life genetic testing clinical oncology asco annual meeting
Oncology Peer Review On-The-Go
S1 Ep111: Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Oncology Peer Review On-The-Go

Play Episode Listen Later May 27, 2024 21:37


Through elaborate multidisciplinary collaboration, institutions with National Accreditation Program for Rectal Cancer (NAPRC) standards can deliver a “high level of care” in the surgical treatment of patients with rectal cancer, according to Steven Wexner, MD, PhD, and Arielle Kanters, MD. In a conversation with CancerNetwork®, Wexner and Kanters detailed the history and advancement of the NAPRC as an interdisciplinary initiative to improve the outcomes of those undergoing surgery for rectal cancer. Wexner is the chair in the Department of Colorectal Surgery and director of the Ellen Leifer Shulman & Steven Shulman Digestive Disease Center at Cleveland Clinic, Florida, the founding chair of the NAPRC for the American College of Surgeons Commission on Cancer, and part of the executive committee of the Commission on Cancer. Kanters is a colorectal surgeon, associate fellowship program director, and surgeon leader of the NAPRC program at Cleveland Clinic Main Campus. Wexner spoke about the inspiration for developing the NAPRC as a mission to elevate the level of surgical outcomes in patients with rectal cancer across the United States to those he observed in European countries such as the United Kingdom and Scandinavia. He enlisted leaders from organizations including the Society of Surgical Oncology and the College of American Pathologists to outline and apply appropriate standards for surgical care in rectal cancer. Additionally, Kanters highlighted how enforcing precise guidelines and compliance measures through the NAPRC program facilitates multidisciplinary efforts with colleagues who specialize in radiology and pathology. She stated that these principles help individuals develop their skills across each department, thereby maintaining a high level of treatment for patients with rectal cancer.  Findings from a study published in the Journal of the American College of Surgeons indicated that mortality and complication rates appeared to be lower for patients who received surgery for rectal cancer at NAPRC-accredited institutions compared with those who were treated at non-accredited practices. Wexner and Kanters also discussed how potential advancements related to the use of neoadjuvant or adjuvant therapy may further improve patient outcomes in the field. Additionally, they spoke about updated research on immunotherapy and other modalities that they anticipate at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Reference Harbaugh CM, Kunnath NJ, Suwanabol PA, Dimick JB, Hendren SK, Ibrahim AM. Association of National Accreditation Program for Rectal Cancer Accreditation with outcomes after rectal cancer surgery. J Amer College Surg. Published March 28, 2024. doi:10.1097/XCS.0000000000001064

Oncology Peer Review On-The-Go
S1 Ep110: Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Oncology Peer Review On-The-Go

Play Episode Listen Later May 20, 2024 25:11


In a conversation with CancerNetwork® at Memorial Sloan Kettering Cancer Center (MSKCC), Neil M. Iyengar, MD, spoke about developments and challenges in his career as a medical oncologist and clinical investigator as well as ongoing research efforts in improving outcomes among patients with breast cancer.  Iyengar, a breast oncologist in in the Department of Medicine at MSKCC and Weill Cornell Medicine in New York City, New York, as well as the co–editor-in-chief of the journal ONCOLOGY®, detailed his work in the emerging field of exercise oncology. Based on preclinical data supporting the potential anti-tumor effects of exercise, he and his colleagues are organizing several clinical trials to validate whether exercise intervention can improve cancer-specific end points. Although some findings may support implementing exercise as part of a cancer treatment plan, Iyengar noted the observational and self-reported nature of the prior data and said that it would be necessary to test exercise intervention in the same way “you would develop any new drug for treating cancer.” Additionally, Iyengar discussed the fulfillment of ensuring patient care, a passion that has fueled his interest in lifestyle interventions such as exercise oncology. He highlighted how his cancer treatment philosophy extends beyond the goal of reducing tumor volumes to safeguarding the patient's physical and emotional well-being. “You can certainly hammer away at a tumor and give all kinds of chemotherapy and anti-cancer therapies, but if that [patient] is feeling miserable and has no quality of life and a short duration of response to that therapy, that's not necessarily the type of outcome that I would consider to be successful,” Iyengar said. “If you're able to either control or cure a cancer while also improving a [patient's] quality of life and general well-being, that's the kind of outcome that I strive for. When I see that in my patients and in the patients of my colleagues, that certainly brings a lot of fulfillment.” Iyengar also highlighted how he found excitement and passion in off-hours responsibilities to help achieve work-life balance. Looking ahead, he spoke about data on anti-estrogen agents, antibody drug conjugates, and other breast cancer treatment strategies that he is looking forward to hearing at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Oncology Times - OT Broadcasts from the iPad Archives
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Aug 11, 2023 9:17


Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary dissection in older women with clinically node-negative breast cancer from Mariam Rana, MD, FRCSC, Oncology Surgeon with the University of Saskatchewan in Canada College of Medicine, in discussion with Robert Hills, DPhil, Chair of Medical Statistics at Oxford University Nuffield Department of Population Health, who leads the secretariat for the Early Breast Cancer Trialists' Collaborative Group. They discuss Rana’s ASCO poster that found the omission of axillary surgery to stage the axilla may be associated with a higher risk of overall mortality in older women with early-stage breast cancer, compared to those who have this surgery.

Cancer.Net Podcasts
2023 Research Round Up: Breast Cancer, Lymphoma, Multiple Myeloma, and Brain Tumors

Cancer.Net Podcasts

Play Episode Listen Later Jul 27, 2023 28:19


ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting, and explain what it means for people with cancer. In today's episode, our guests will discuss new research in breast cancer, lymphoma, multiple myeloma, and brain tumors. First, Dr. Norah Lynn Henry discusses new research in early stage and metastatic breast cancer. Dr. Henry is Professor and Interim Chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and the Breast Oncology Disease Lead at the Rogel Cancer Center. She is also the 2023 Cancer.Net Associate Editor for Breast Cancer. You can view Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of the most exciting new research in breast cancer that was presented at the 2023 ASCO Annual Meeting. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both early-stage and metastatic breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We treat those cancers with anti-estrogen or anti-endocrine treatments, which block estrogen or lower estrogen levels. Other breast cancers are called HER2-positive. These are often more aggressive cancers. But because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2. These are called triple-negative breast cancer and are also often aggressive cancers. Most of the results I'm going to highlight today are treatments for estrogen receptor-positive and HER2-negative breast cancer. One of the main stories from the ASCO Annual Meeting was the result of the NATALEE trial. At the present time, for patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who were at high risk of having their breast cancer come back, the currently recommended treatment is anti-endocrine therapy. Based on the results of a prior trial called monarchE, we also consider adding a medicine called abemaciclib, which turns off some enzymes in the cell that are called CDK4 and CDK6, which are known to make estrogen receptor-positive breast cancer cells grow. Abemaciclib can further reduce the risk of cancer recurrence compared to endocrine therapy alone, but it does have some side effects, most commonly, diarrhea. In the NATALEE trial, which was presented for the first time at this ASCO meeting, researchers studied a similar type of medication called ribociclib. It acts similarly to abemaciclib, although it is more likely to cause low blood counts and less likely to cause diarrhea. Ribociclib is currently routinely used in combination with anti-endocrine therapy to treat patients with metastatic estrogen receptor-positive breast cancer but is not yet routinely used in the early-stage setting. In the NATALEE trial, patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who are at high risk of breast cancer recurrence were enrolled. Half the patients were treated with just standard anti-endocrine therapy and half also received ribociclib for 3 years. After the 3-year treatment period, those who received both ribociclib and anti-endocrine therapy were about 25% less likely to have their cancer come back compared to those who received only anti-endocrine therapy. Overall, the medication was quite well tolerated. It is important to note that this drug is not yet FDA-approved in the setting. The remaining trials I will highlight are for treatment of metastatic breast cancer. There were many trials examining how best to use drugs that we are actually already using in the clinic. For example, many presentations were about the CDK4/6 inhibitors that I just mentioned. Typically, patients who have just been diagnosed with estrogen receptor-positive, HER2-negative metastatic breast cancer get treated with anti-endocrine therapy plus a CDK4/6 inhibitor. One trial called SONIA examined whether this is the right approach, or whether patients should just get the anti-endocrine therapy up front and hold off on starting the CDK4/6 inhibitor medication until a later time. It appears that this delayed approach would reduce symptoms as well as cost of the medication, while not reducing benefit from the treatment. Therefore, it appears it is likely fine for some patients to get just anti-endocrine therapy alone initially. However, we don't know how to identify those patients. Researchers are still figuring out which patients should follow this new treatment plan and which should keep getting the double therapy at the beginning. Some more to come in the future. There was a different trial called PADA-1 that included patients taking anti-endocrine therapy and the CDK4/6 inhibitor, palbociclib, upfront. Those patients were monitored using a blood test, looking for a mutation or a change in the estrogen receptor in the cancer. Patients who had that mutation either remained on the same treatment that they'd been on or switched to the next line of therapy, even though their scans didn't show any progression of their cancer. Overall, this switching strategy looks like a very promising approach for managing patients since it may help patients' cancer respond to treatment for a longer period of time. Although this approach is not yet officially recommended according to our guidelines. In another example, many patients with all types of metastatic breast cancer are treated with a drug called capecitabine, also known as Xeloda. Although this drug is effective for many cancers, many patients experience hand-foot syndrome, nausea, diarrhea, and mouth sores. In the X7-7 clinical trial, the researchers compared the official standard FDA-approved dose based on a patient's height and weight and given for 14 days followed by 7 days off. That was compared to a fixed dose of treatment given 7 days on and 7 days off. The trial found that the fixed-dose regimen was easier to tolerate, but importantly, the benefit from the 2 doses and schedules of treatment appears to be similar. Therefore, we will likely be using this lower dose, 7 days on and 7 days off, for most of our patients who receive treatment with capecitabine for metastatic breast cancer, since it is likely to improve their quality of life while not negatively impacting the potential benefit they receive from the therapy. There were a lot of other research findings presented that are related to treatment for both early-stage and metastatic breast cancer at the meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, including a new antibody-drug conjugate against HER2, as well as other new anti-endocrine and targeted treatments. We eagerly await the results of large, randomized trials so the drugs that work can be used to treat patients with breast cancer. But for now, that's it for this quick summary of important research from the 2023 ASCO Annual Meeting. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. Next, Dr. Christopher Flowers discusses new research in lymphomas and multiple myeloma. Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and Division Head ad interim of Cancer Medicine. He is also the 2023 Cancer.Net Associate Editor for Lymphoma. You can view Dr. Flowers' disclosures at Cancer.Net. Dr. Flowers: Hello. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma and interim division head for cancer medicine at the University of Texas MD Anderson. And it's my pleasure to talk to you today in this Cancer.Net podcast about latest updates in the hematological malignancies focused on lymphoid cancers from the American Society of Clinical Oncology Annual Meeting. The ASCO Annual Meeting every year is an exciting time for latest updates in the care of patients with cancer. And in particular this year, there were 3 abstracts that I'd like to highlight that were presentations at this meeting about lymphoid malignancies that have potential significant impact for patients over time. The first 2 come from a special session that was on late-breaking abstracts that were latest advances from clinical trials. The first is from the ZUMA-7 trial. This is a trial looking at axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. The CAR T-cell trial in question here was led by Jason Westin, who's a colleague of mine at MD Anderson. And MD Anderson is a partner with Kite pharmaceutical company that is a manufacturer of this and has a research alliance with that group. In the ZUMA-7 trial, this was a trial that involved the use of CAR T-cell therapy in comparison to standard-of-care therapy, which typically would be aggressive chemoimmunotherapy followed by autologous stem cell transplantation for patients with relapse of large B-cell lymphoma. As many of you may know, large B-cell lymphoma is a kind of lymphoma that is potentially curable with standard frontline therapy. And when patients relapse, the standard of care historically had been for patients to receive autologous stem cell transplantation, which is also potentially a curative therapy. This trial to do a ZUMA-7 trial compared patients who received the typical standard of care, the autologous stem cell transplant following the aggressive chemoimmunotherapy regimen for patients who had relapsed early after their initial therapy, so within 12 months, or were refractory, meaning that they did not respond to their initial therapy. And this was compared to the axicabtagene ciloleucel or axi-cel CAR T-cell therapy. The initial publication of the trial came out in the New England Journal of Medicine in 2022 and showed that the event-free survival for patients who receive CAR T-cell therapy was superior. This update of the ZUMA-7 trial at the ASCO Annual Meeting that was presented by my colleague, Jason Westin, discussed the overall survival of the study, and in this update, it showed that overall survival was also improved for patients who received axi-cel as opposed to standard-of-care therapy. And now with a median follow-up of a little bit more than 47 months, axi-cel demonstrated superiority that was statistically significant and clinically meaningful over the traditional standard of care. In that same session, there was another trial looking at CAR T-cell therapy for patients with multiple myeloma. This was a BCMA-targeted CAR T-cell therapy that was presented by Dr. Dhakal in that session providing results from the CARTITUDE-4 global randomized phase 3 clinical trial. That was a trial that involved 419 patients where patients were randomized to cilta-cel CAR T-cell therapy for myeloma or standard-of-care therapy, which in this case included combination therapy. And in this trial, this showed that single agent with a single cell-to-cell infusion significantly improved progression-free survival versus standard of care for patients with multiple myeloma who had 1 to 3 prior lines of therapy and were refractory to lenalidomide. This is also a meaningful advance for patients with this disease. And the final abstract that I'll mention is an abstract that was presented by Dr. Alex Herrera from City of Hope and was presented in the Plenary session. And it was really exciting to see a Plenary session presentation focusing on lymphomas. So this trial presented by Dr. Herrera was led by the Southwest Oncology Group. Dr. Sara Ahmed from MD Anderson, from my institution, was a participant and actively engaged in this clinical trial. This trial was a success in a number of ways. First, it involved both pediatric and adult patients and is one of the first trials of its kind to involve both large populations of patients with pediatric lymphomas as well as adults with lymphomas. It helps to consolidate the approaches that we use for Hodgkin lymphoma, both in the pediatric population and the adult population. It also represents a major advance in the ways that we conduct clinical trials in the United States in that this clinical trial finished ahead of schedule in terms of completion of the trial with collaboration from the adult and pediatric groups across the National Clinical Trials Network. As I mentioned, this was presented by Dr. Alex Herrera in the Plenary session and involved patients with stage 3, 4 Hodgkin lymphoma, where patients were randomized 1 to 1 either to receive an anti-PD-1 therapy, nivolumab, with chemotherapy, the AVD chemotherapy regimen, or the antibody-drug conjugate, brentuximab vendotin, combined with that same AVD chemotherapy. And what this showed in 994 patients who were enrolled from 2019 to 2022 was that there was a benefit for patients who received the combination of nivolumab AVD or NAVD versus the group that received brentuximab and AVD. It improved the progression-free survival in patients with advanced-stage Hodgkin lymphoma. In this trial, few immune-related adverse events were observed and a lesser number of patients went on to receive radiation therapy, which is also a benefit for patients with Hodgkin lymphoma. And this concludes my presentation of abstracts at the ASCO Annual Meeting and really exciting advances for patients with lymphoma that were presented this year. ASCO: Thank you, Dr. Flowers. Finally, Dr. Roy Strowd discusses new research in treating brain tumors, including those in people with von Hippel Lindau syndrome. Dr. Strowd is a neurologist and neuro-oncologist at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also the 2023 Cancer.Net Associate Editor for Central Nervous System Tumors. You can view Dr. Strowd's disclosures at Cancer.Net. Dr. Strowd: Hello, everyone. This is Roy Strowd. I'm a physician neuro-oncologist at Wake Forest University School of Medicine in our comprehensive cancer center. And I'm really excited to be with you for this podcast on important CNS or brain tumor updates from the 2023 ASCO Annual Meeting. I don't have any relevant disclosures for the research that we'll discuss today. It was a really exciting meeting. It was actually a really fun meeting to be a brain tumor doctor at ASCO this year. So I'm really excited to talk with you about some important updates. And I think it's actually a really important time to be a patient and a caregiver and know some of the things going on in brain tumor care. So I'm going to dive into 3 studies. And one that we just have to talk about, and this was a really exciting study called the INDIGO study. At ASCO, if you present a study, you want to have a Plenary presentation, you want to be up on the big stage presenting your work. And brain tumor studies aren't always on the big stage. We just haven't had enough really good treatments out there for brain tumor patients over the years. And this year, we had a Plenary presentation, a really big study, making a big splash. And that was this INDIGO study. So I'm going to spend a few minutes talking about that study. I want brain tumor patients and caregivers to know about this and know about some of the important updates from the Annual Meeting. The study was called the INDIGO study, and it's a phase 3 study. So when you think about clinical trials, there's a phase 1, phase 2, phase 3. That phase 3 is that last step, that last hurdle that a drug needs to overcome to move towards approval. And a positive phase 3 study is really exciting for the field and means that we may have a new treatment that will change how we take care of brain tumor patients. And that's what this study was. It was also a really unique study. So it's looking at a different group of brain tumor patients, patients that have an IDH mutant glioma. Most common brain tumors that we see are the glioblastomas. And those are often and really, by rule, IDH wild-type. IDH is a gene. It's called the isocitrate dehydrogenase gene. And it's one of these really important genes for us to understand how brain tumors are going to work and how they act and it turns out, with this study, how they may respond to treatment. So this study looked at enrolling patients that had an IDH-mutant low-grade glioma, or a grade 2 glioma. Those are those often slower-growing, but they continuously grow tumors that occur early in life, typically in the 30s or 40s for young people. And we haven't really had a lot of good treatments for these patients. And so this study looked at giving a new drug that's called vorasidenib. It's hard to say vorasidenib. And it's an IDH mutant inhibitor. So it attacks that IDH mutant gene that makes these tumors what they are. And it's been undergoing development for many years. It's an exciting treatment because it's what we call a molecularly targeted treatment. It specifically targets that IDH gene that makes the low-grade tumors low-grade tumors. This study enrolled 331 patients, so a large group of patients. Half of those patients received the drug, the vorasidenib, and half received placebo. And that's pretty uncommon in cancer. We don't often do studies that are placebo-controlled studies. But for these patients, there's often not a good treatment early in the course, they get surgery. And for patients that don't need an additional treatment, we do surgery and then we wait and watch and see what happens. And that gives us an opportunity as a brain tumor community to figure out whether this type of treatment will help prevent the need for a next treatment, prevent the need for radiation and chemotherapy. And so that's what was looked at in this study. And there was some really exciting data. So I'm going to go through a few numbers, but we just got to talk about these numbers because they're really important. So at 14 months, 28% of the patients receiving the drug vorasidenib had progressions. That's about a quarter of patients compared to half that received placebo. So that's a big improvement in the number of patients whose tumor grew. So this drug prevented tumor growth in these patients. And that's exactly what we want. That's why we develop drugs, is to prevent tumor growth. When we look at the time that those patients had until they needed a next treatment or until their tumor grew, it was over 2 years of time patients receiving the drug when their tumor grew versus less than a year, 11 months for those receiving placebo. So it's adding a lot of time for brain tumor patients without tumor growth or without needing another treatment. And typically, these patients with low-grade gliomas would need something like radiation therapy or chemotherapy. And those are good treatments, and we need those treatments. But they can have toxicity. And so this is the type of drug that could prevent that toxicity, cognitive decline, other problems that can happen with chemotherapy that those patients didn't potentially suffer. So there are some important things that we learned from the INDIGO study that I would want you to take away, kind of what do these data mean? The first is that we can target this IDH gene. And that's really important for our field. And it means if you're a brain tumor patient, knowing whether your tumor is IDH mutant or IDH wild-type is important, and that's something I want brain tumor patients to ask me as a neuro-oncologist and ask their cancer doctor because that's important in deciding treatment for them. The second is this medicine vorasidenib, it gets into the brain. And that's one of the big challenges that we have in brain tumor care in developing drugs is we need things that get into the brain. And this study really shows that this is a good medicine. There's a number of IDH inhibitors, but this medicine vorasidenib is one that we want to specifically think about for our patients. And this is a practice-changing study. So for the first time, we now have a treatment that works for grade 2 gliomas and really prevents the need for radiation therapy and chemotherapy. So those are 3 important things to take away from this. There's a number of things that we don't yet know. This medicine is not available. So patients coming in and emailing me and calling me, we don't have it yet. And after a big phase 3 study like this, this is announced. There's still a number of steps that need to happen to make sure that this can be delivered to patients safely and we can get it out there. And that's in partnership with groups like the FDA, the Food and Drug Administration, and others. So this is an important conversation to have with patients, neuro-oncologists, and to know that this is something that's on the horizon. Two other things is we don't know if this is going to work for all brain tumors. In particular, for these IDH wild-type glioblastomas, the most common brain tumor, this probably is not a good therapy that we don't have any data to suggest that it would work. They don't have that IDH mutation. And so this is important for some brain tumor patients but not for everybody. And that needs to prompt a conversation with the cancer doctor. And it may not work at all times. So there's some data to suggest that this is really a drug that's best given early in the course of treatment and not later on. And so it is something that I want my patients to be aware of at the first time that I see them so we can be deciding what kind of the right time is. So I want to give folks 2 take-homes from this study and summarize a few of these things that we heard about because it's such an important study. So what are the 2 take-homes from the INDIGO Study? The first that I wrote down is targeting IDH mutation in glioma works. And that's a groundbreaking discovery from this. This is really important for our field. IDH mutations have been important to diagnose brain tumors but have never been really a therapeutic target. And this changes the landscape, and we can now target IDH mutations in gliomas. And that's really important. The second thing, the second real take-home message, is we can safely delay radiation therapy and chemotherapy in some patients with these lower-grade gliomas, potentially with IDH mutation and IDH inhibition. And that's really important. Chemotherapy and radiation therapy are important, but if we can delay those treatments and prevent side effects, that could be helpful for some of our patients. So really important update from ASCO and what I want to spend most of the time on our podcast focusing on this INDIGO study. But there were a bunch of other things going on in brain tumors at ASCO, as there always are. And I want to highlight 2 studies about some things that the groups of patients may be interested in knowing that happened at the meeting. The first is a study called the INB-200 study. And this is a phase 1 study, so it's earlier in development. But it's an immunotherapy study. And brain tumor patients and caregivers will know that we've really wanted to find an immunotherapy that works for brain tumors. And we haven't yet. And we're still not there, but this study is an important step in that direction. So this study from a group at the University of Alabama looked at something called gamma delta T cells. And T cells are really important. They're part of the anti-tumor response. They're what the body uses to attack the tumor. So we like those T cells. And particularly, these gamma delta T cells are important in targeting tumor cells in glioblastoma cells. They're also unique. They can avoid the toxicity of chemotherapy. Radiation therapy and chemotherapy suppresses the T cells. They make some go down, or decreased in number, which is not what we want. And these gamma delta T cells were genetically created so that they were resistant to chemotherapy. And that's really, really important. We want an immunotherapy that works and one that isn't suppressed by our other treatments. And that's been a real barrier for glioma patients. So in this phase 1 study, they found the right dose of these gamma delta T cells, and that's the goal of a phase 1 study. But there were some early signs that this may be changing the tumor. One of the patients underwent surgery before and after they got this infusion. And we were able to see this. Investigators were able to see the gamma delta T cells up in the tumor. So this doesn't change practice. Patients don't need to go out and seek out the gamma delta T cells yet. But it's one of those early findings that says that we need to keep looking at immunotherapy. And as a community, this is something we need to keep focusing on. And then the last abstract and study I wanted to focus on is for a rare disease. This would not be something that would be relevant for all of our listeners and the brain tumor patients but for a subgroup of patients that have a condition called VHL, or von Hippel-Lindau. And von Hippel-Lindau is a genetic condition. So, most brain tumors are not inherited. You don't get it from a mom or a dad or pass it on, except for these patients, you do. And it comes from a gene that's inherited in families called the VHL or the von Hippel-Lindau gene. And these patients are predisposed to get tumors all throughout the body and the kidneys and the brain and the eye. And this is a lifelong disease where these tumors can really grow slowly over time and cause significant problems. And in the past few years, there's been a new treatment called belzutifan. Belzutifan is the name of this drug that has been shown to be effective in the kidney tumors for patients with VHL. And at ASCO this year, there was a new study showing that it's also effective in treating the brain tumors for these patients. And that's really important. We just haven't had a treatment other than surgery or radiation therapy for these tumors. And oftentimes, they grow after surgery and radiation therapy and we need an additional treatment. So in this study, the investigators looked at, "Does this drug belzutifan work for treating the CNS tumors, hemangioblastoma?" And found that around 50% of patients had a response, so a shrinkage in the size of the tumor. 90% of patients had control of their brain tumor disease, which is really important. And it worked really quickly, so it worked in about 3 to 5 months, which is shorter than what we would see for the kidney tumors. So that's exciting news for VHL patients, patients with von Hippel-Lindau, and another important update from the 2023 ASCO. So thanks for listening to this update of CNS brain tumors at the 2023 ASCO Annual Meeting. Again, I'm Roy Strowd, a neuro-oncologist at Wake Forest University School of Medicine. Delighted to bring you this brief summary of new research in the field. ASCO: Thank you, Dr. Strowd. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Oncology Data Advisor
Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD

Oncology Data Advisor

Play Episode Listen Later Jun 28, 2023 7:24


Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Richard Newcomb, MD!

Oncology Data Advisor
Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD

Oncology Data Advisor

Play Episode Listen Later Jun 28, 2023 1:39


Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Dr. Shubham Pant!

cancer trial american society pant tract shubham biliary clinical oncology asco annual meeting
Oncology Data Advisor
Leveraging Community-Academic Partnerships for Latinx AYA Cancer Survivors With Stephanie Smith, MD

Oncology Data Advisor

Play Episode Listen Later Jun 28, 2023 9:27


Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Stephanie Smith, MD!

Oncology Data Advisor
Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD

Oncology Data Advisor

Play Episode Listen Later Jun 28, 2023 6:57


Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Thomas Hutson, MD!

Oncology Data Advisor
Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD

Oncology Data Advisor

Play Episode Listen Later Jun 28, 2023 11:54


Listen to this live interview recorded by Oncology Data Advisor at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Timothy Cloughesy, MD!

Oncology Data Advisor
Coaching Cancer Survivors Through Digital Health: Robin Lally, PhD, and Marilyn Hammer, PhD

Oncology Data Advisor

Play Episode Listen Later Jun 27, 2023 10:12


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Robin Lally and Marilyn Hammer!

Oncology Data Advisor
Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD

Oncology Data Advisor

Play Episode Listen Later Jun 27, 2023 7:16


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Yan Leyfman, MD!

Oncology Data Advisor
Partnering With Patients Through Advocacy With Allison Rosen

Oncology Data Advisor

Play Episode Listen Later Jun 27, 2023 8:59


Listen to this live interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Allison Rosen!

patients advocacy partnering american society rosen clinical oncology asco annual meeting
OBR Peer-Spectives
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now

OBR Peer-Spectives

Play Episode Listen Later Jun 26, 2023 13:36


Although findings have suggested that adjuvant osimertinib is beneficial in early-stage non-smallcell lung cancer (NSCLC), some concerns have persisted. Balazs Halmos, MD, MS, associate director of clinical science, and director of both thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center in New York, says that “all these doubts have been shifted away,” given recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Halmos speaks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles, about data from the ADAURA trial and other studies. Dr. Halmos says that the new evidence is “not just practice-affirming” butcan be considered “practice-expanding,” resulting in complicated questions that necessitate morethorough collaborations among oncologists, surgeons, pathologists, and radiologists.

Oncology Data Advisor
Social Media's Effect on Informed Decision Making in Cancer Treatment

Oncology Data Advisor

Play Episode Listen Later Jun 20, 2023 14:01


In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill University Health Center, sit down to talk about Ms. Morena's thesis topic and research, How reliable are post-mastectomy breast reconstruction videos on YouTube?, which she presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Her presentation encompasses the effects of social media platforms, specifically YouTube, on breast cancer patients.

OBR Peer-Spectives
“Don't Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer

OBR Peer-Spectives

Play Episode Listen Later Jun 20, 2023 13:21


How should community oncologists best approach ESR1 mutations in breast cancer, given the latest findings? Recent data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and elsewhere have shed light on issues related to ESR1 testing and treatment selection. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology oncology at Cedars-Sinai Cancer in Los Angeles, speaks with Hope Rugo, MD, professor of medicine in the division of hematology and oncology, department of medicine, and director of breast oncology and clinical trials education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, about how to put new findings into practice. Dr. Rugo provides key recommendations, as she explains that “It's really important that we don't just throw drugs together in clinical practice.”

Oncology Peer Review On-The-Go
S1 Ep74: Oncology On-The-Go Podcast: ASCO 2023 Recap

Oncology Peer Review On-The-Go

Play Episode Listen Later Jun 19, 2023 39:46


Ritu Salani, MD, and Tanios S. Bekaii-Saab, MD, FACP, spoke with CancerNetwork® about key findings presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and how they may affect clinical practice for gynecologic cancer and gastrointestinal cancer. Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, discussed presentations on the treatment of ovarian cancer and other gynecologic malignancies. These included data on dostarlimab-gxly (Jemperli) in advanced or recurrent endometrial cancer in the phase 3 RUBY trial (NCT03981796), mirvetuximab soravtansine-gynx (Elahere) in folate receptor alpha–high platinum-resistant ovarian cancer in the phase 3 MIRASOL trial (NCT04209855), and a bevacizumab (Avastin)-based regimen in newly diagnosed ovarian cancer in the phase 3 DUO-O trial (NCT03737643). Bekaii-Saab, leader of the Gastrointestinal Cancer Program at the Mayo Clinic Comprehensive Cancer Center; medical director of the Cancer Clinical Research Office; vice chair/section chief for Medical Oncology, Department of Internal Medicine, at Mayo Clinic, Phoenix, Arizona; and the Gastrointestinal Cancer chair for the ONCOLOGY® tumor board, detailed findings from presentations in the gastrointestinal cancer space. He discussed data on fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic colorectal cancer (CRC) in the phase 2 DESTINY-CRC02 study (NCT04744831), sotorasib (Lumakras) in advanced solid tumors with KRAS G12C mutations in the phase 1b/2 CodeBreaK 101 trial (NCT04185883), and bevacizumab plus atezolizumab (Tecentriq) in metastatic CRC in the phase 2 AtezoTRIBE trial (NCT03721653). Don't forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Oncology Data Advisor
Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 4:24


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Michael Halpern, MD!

md drug waste reducing dose american society rounding bevacizumab michael halpern clinical oncology asco annual meeting
Oncology Data Advisor
Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 9:31


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Kathleen Moore, MD!

Oncology Data Advisor
Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 5:57


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Kohei Shitara, MD!

Oncology Data Advisor
Payment Reform Through the Enhancing Oncology Model With Lalan Wilfong, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 4:49


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Lalan Wilfong, MD!

Oncology Data Advisor
Understanding Sexual Orientation and Gender Identity Data Collection: Mandi Pratt-Chapman, PhD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 9:32


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Mandi Pratt-Chapman, PhD!

Oncology Data Advisor
Molecular Analyses of Sacituzumab Govitecan in Urothelial Carcinoma With Manoj Bupathi, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 6:04


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Manoj Bupathi, MD!

md american society molecular analyses manoj carcinoma clinical oncology asco annual meeting
Oncology Data Advisor
Effects of Employment Disruptions Experienced During Cancer With Michael Halpern, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 8:06


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Michael Halpern, MD!

cancer md effects disruption employment experienced american society michael halpern clinical oncology asco annual meeting
Oncology Data Advisor
Accelerated Brain Age in Survivors of Childhood Cancer With Nicholas Phillips, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 5:56


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Nicholas Phillips, MD!

md survivors american society accelerated childhood cancer brain age clinical oncology asco annual meeting nicholas phillips
Oncology Data Advisor
Impact of Social Determinants of Health on TNBC Genetic Testing With Nicholas Robert, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 6:12


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Nicholas Robert, MD!

Oncology Data Advisor
Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD

Oncology Data Advisor

Play Episode Listen Later Jun 15, 2023 4:40


Listen to this live podcast from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Oncology Data Advisor and Noelle Cloven, MD!

trial md american society artistry alfa ovarian cancer clinical oncology asco annual meeting
Oncology Data Advisor
Pickles Group: Supporting Kids During Their Parents' Cancer With Cassy Horton

Oncology Data Advisor

Play Episode Listen Later Jun 9, 2023 7:34


Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Cassy Horton!

Oncology Data Advisor
Renal Cell Carcinoma Research and Shared Decision Making With Bradley McGregor, MD

Oncology Data Advisor

Play Episode Listen Later Jun 9, 2023 7:28


Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Bradley McGregor, MD!

Oncology Data Advisor
Social Determinants of Health in Triple-Negative Breast Cancer Genetic Testing With Barb Kunz, LCGC

Oncology Data Advisor

Play Episode Listen Later Jun 9, 2023 8:06


Listen in to this podcast recorded live at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting with Barb Kunz, MS, LCGC!

Oncology Data Advisor
HemePath Hub, a Unique Learning Opportunity: Dr. Aamir Ehsan and Dr. Bridget Herschap

Oncology Data Advisor

Play Episode Listen Later Jun 9, 2023 6:00


Listen in to this podcast recorded live at the American Society of Clinical Oncology (ASCO) Annual Meeting with Aamir Ehsan, MD, and Bridget Herschap, MD, of CorePath Laboratories!

The Bell2Bell (B2B) Podcast
Bell2Bell Podcast featuring Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX)

The Bell2Bell (B2B) Podcast

Play Episode Listen Later Jun 8, 2023 6:31


Bell2Bell's latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. This episode was recorded live at the venue hosting the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical oncology meeting of the year. Last year, there were 30,000 attendees at the meeting and another 12,000 tuning in electronically. This year's event is estimated to be the same in size.  Dr. Berger explained why this year has been such a great one for Genprex. To hear an exciting summary of the company's recent accomplishments and his expectations for the future, tune into this episode. 

nasdaq american society berger chief medical officers podcast dr mark berger clinical oncology asco annual meeting
The Bell2Bell (B2B) Podcast
Bell2Bell Podcast featuring Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX) [Video Edition]

The Bell2Bell (B2B) Podcast

Play Episode Listen Later Jun 8, 2023 6:31


Bell2Bell's latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes. This episode was recorded live at the venue hosting the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest clinical oncology meeting of the year. Last year, there were 30,000 attendees at the meeting and another 12,000 tuning in electronically. This year's event is estimated to be the same in size.  Dr. Berger explained why this year has been such a great one for Genprex. To hear an exciting summary of the company's recent accomplishments and his expectations for the future, tune into this episode.   

Oncology Data Advisor
Increasing Medical Student Confidence When Treating LGBTQIA+ Patients

Oncology Data Advisor

Play Episode Listen Later Aug 22, 2022 8:16


Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.

Oncology Data Advisor
Tackling Violence and Stigmatization to Decrease Disparities for Transgender Patients: Ash Alpert

Oncology Data Advisor

Play Episode Listen Later Aug 5, 2022 7:49


At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.

Oncology Peer Review On-The-Go
S1 Ep57: Oncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCO

Oncology Peer Review On-The-Go

Play Episode Listen Later Jun 30, 2022 44:23


In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.  During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. The co-hosts also reviewed surprising results from phase 3 PALOMA-2 trial (NCT01740427), which failed to show an overall survival benefit with use of palbociclib (Ibrance) plus letrozole in patients with estrogen receptor–positive/HER2-negative advanced breast cancer vs letrozole alone.  Additionally, Tolaney discussed her presentation of the phase 3 monarchE trial (NCT03155997) that explored adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer.  Overall, both investigators said they enjoyed coming back to in-person conferences and how they hope the trend of practice-changing trials continues with future conferences.  Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Oncology Data Advisor
Discussing Patient-Reported Hope in Early Phase Clinical Trials With Debra Lundquist, PhD, RN

Oncology Data Advisor

Play Episode Listen Later Jun 24, 2022 7:24


At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants.

Oncology Data Advisor
ASCO Podcast Beth Peck

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 3:16


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society peck asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Aamir Ehsan

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 6:53


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco ehsan aamir clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Matthew Schabath

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 5:06


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Kathi Mooney

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 10:17


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society mooney asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Jessica Jones

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 4:34


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society jessica jones asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Colin Ferro

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 3:23


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society ferro asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Jeannine Brant

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 6:52


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society brant asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Megan - Claire Chase

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 14:53


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco claire chase clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Ian Krop

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 8:48


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco krop clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast David Penberthy

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 10:11


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco podcast david clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Danet Peterson

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 6:03


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago peterson american society asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Dan Gombos

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 6:19


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco podcast dan clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Jason Mouabbi

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 3:10


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Navdeep Dehar

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 2:34


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco navdeep clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Urvi Shah

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 16:00


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago shah american society asco urvi clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Wendy London

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 7:05


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco clinical oncology asco annual meeting conveymed
Oncology Data Advisor
ASCO Podcast Sam Kareff

Oncology Data Advisor

Play Episode Listen Later Jun 21, 2022 2:11


This playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don't forget to follow us on social media for news, exclusive interviews, and more!

chicago american society asco clinical oncology asco annual meeting conveymed
OBR Peer-Spectives
Most Patients with BRAF-mutant Metastatic Melanoma Benefit from First-line Immunotherapy

OBR Peer-Spectives

Play Episode Listen Later Jun 16, 2022 12:44


Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who receive ipilimumab plus nivolumab prior to receiving a BRAF/MEK inhibitor. But not all patients fit that paradigm. Listen as Dr Atkins shares which patients he starts on immunotherapy and when he thinks is the best time for crossover to a targeted agent.

Physician's Weekly Podcast
Phase 3 DESTINY-Breast03 Impresses at ASCO 2022

Physician's Weekly Podcast

Play Episode Listen Later Jun 7, 2022 18:57


Welcome to this episode of Physician's Weekly  podcast. I am your host Dr Rachel Giles, from Medicom Medical Publishers in collaboration with Physician's Weekly. This week, we have 2 really interesting interviews about very different topics. I will start with the second interview. The 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, was held 3 -7 June 2022 in Chicago, IL. One of the most covered topics talked in the hallways and you may have read in newspapers, was about precision treatment in aggressive breast cancer.  It all started 24 years ago, when a drug called Herceptin changed how doctors treat breast cancer. Its approval in 1998 made it possible to target the aggressive breast tumors tied to a gene called HER2. Other drugs quickly followed Herceptin and, over the years since, have substantially improved survival for people with the disease.A quarter of a century later, another shift in treatment could be on the horizon. At the American Society of Clinical Oncology meeting, researchers presented results proving that, for the first time, a targeted medicine, called trastuzumab deruxtecan (or T-Dxd for short) can help metastatic breast cancer patients whose tumors express only low levels of HER2. Because many more patients may soon be eligible for treatment with T-Dxd, we focused on a safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer.  We speak with Prof. Guiseppe Curigliano (University of Milan, Italy) to learn the latest results. But first, we speak with Sonya M. Sloan, MD, better known as #OrthoDoc, has established herself as a force to be reckoned with in the male-dominated field of Orthopedic Surgery. Licensed to practice medicine in several states, she travels the country as a locum tenens physician. There's a shortage of doctors in America, and all types of facilities need locum tenens providers to relieve physician burnout, maintain patient satisfaction, and stay fully staffed during busy times, or while searching for a permanent doctor. Furthermore, locum tenens helps more people see a provider and receive care, offsetting the physician shortage in underserved areas—especially rural communities, urban areas with health professional shortages, VA hospitals, and Indian Health Service facilities. A 2021 survey indicated that 72% of healthcare facility managers are seeking locum tenens physicians. This is up from 47% in 2016 and up from 39% in 2012. Physician's Weekly senior editor Martta Kelly interviews Dr. Sloan.  Dr. Sloan is the author of  a book titled The Rules of Medicine: A Medical Professionals Guide to Success   Extra reading:  Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690. Epub ahead of print. PMID: 35665782.

Health Professional Radio - Podcast 454422
ASCO 2021 - Blueprint Medicines - ARROW Study Updated Results

Health Professional Radio - Podcast 454422

Play Episode Listen Later Jul 1, 2021 10:01


Dr. Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University discusses updated results from a study of patients with RET fusion–positive NSCLC enrolled in the ARROW study, evaluating the efficacy of GAVRETO (pralsetinib) that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Stephen V. Liu, MD, is an Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University.A Pittsburgh native, Dr. Liu graduated cum laude at Johns Hopkins University with a major in Biology and a minor in Film and Media Studies, before receiving his M.D. at the University of Maryland. He completed his Internal Medicine training at the University of Pennsylvania and a dual fellowship in Hematology and Oncology at the University of Southern California, after which he received further specialized training in genomic medicine at the Translational Genomics Research Institute (TGen) under Dr. Daniel Von Hoff. Dr. Liu has been part of the Thoracic Oncology section and the Experimental Therapeutics Program of Georgetown University since 2013. He is a board-certified medical oncologist with expertise in thoracic malignancies including lung cancer, thymic malignancies and mesothelioma. Dr. Liu has a research focus on the development of novel therapeutic agents and innovative combinations for the treatment of advanced thoracic malignancies. He leads the Thoracic Oncology section and the Phase I Developmental Therapeutics group. His work has been published in journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lancet Oncology, Cancer Discovery and Clinical Cancer Research. He is actively involved in post-graduate education and has been awarded multiple teaching awards for his efforts. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr. Liu has also served as the Chief Editor for Frontiers in Thoracic Oncology since 2014. #ASCO2021 #BlueprintMedicines #ARROW

CancerCast
ASCO 2021 Highlights

CancerCast

Play Episode Listen Later Jun 23, 2021


A review of important research presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and a guide to the scientific jargon to better understand how clinical trials are designed, what is being evaluated and what the research showed. Guest: Manish Shah, MD, Director of the Solid Tumor Service and Gastrointestinal (GI) Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital.Host: John Leonard, MD, world-renowned hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.

Project Oncology®
What Can We Look Forward to at ASCO 2021?

Project Oncology®

Play Episode Listen Later May 18, 2021


Host: Lola Fayanju, MD, MA, MPHS In light of the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Lola Fayanju, an Associate Professor of Surgery and Population Health Sciences at Duke University School of Medicine, shares with us some of the updates in breast cancer care amid the COVID-19 pandemic that she's most excited to learn more about at the conference.

Multiple Myeloma Hub
Isatuximab plus KRd for high-risk NDMM

Multiple Myeloma Hub

Play Episode Listen Later Jun 24, 2020 7:40


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Cancer Center Hamburg, Hamburg, DE. In this podcast she discusses the quadruplet combination of isatuximab with carfilzomib, lenalidomide and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma.In this podcast, Katja Weisel describes the interim results of the phase II GMMG-CONCEPT trial including deep and durable responses, measurable residual disease negativity, remissions, and overall survival of the first 50 patients enrolled. She also discusses the trial design, including the cytogenetic features that classify patients as high risk, as well as the safety profile and dosing regimens. Hosted on Acast. See acast.com/privacy for more information.

acast hamburg american society high risk clinical oncology asco annual meeting isatuximab
Multiple Myeloma Hub
Novel approaches in multiple myeloma: what is unique about CELMoDs?

Multiple Myeloma Hub

Play Episode Listen Later Jun 24, 2020 13:21


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farber Cancer Institute, Boston, US. In this podcast he discusses cereblon E3 ligase modulators (CELMoDs) as a novel approach in the treatment of relapsed/refractory multiple myeloma.Paul Richardson describes how preclinical data have shown CC-92480 to have potent and direct anti-myeloma and immunostimulatory effects. He discusses the results from the phase I, multicenter, international study that combined CC-92480 with dexamethasone in patients with relapsed and refractory multiple myeloma and describes the two dosing regimens (continuous and intensive), patient characteristics, and safety data. Dr Richardson also explains that the results show encouraging, durable responses, particularly for patients that have triple-refractory myeloma, which are a sub-group of patients where there is a significant clinical unmet need. Hosted on Acast. See acast.com/privacy for more information.

Multiple Myeloma Hub
Novel approaches in multiple myeloma: BFCR4350A

Multiple Myeloma Hub

Play Episode Listen Later Jun 18, 2020 6:53


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of Pennsylvania, Philadelphia, US. In this podcast, he discussed the use of BFCR4350A, a novel bispecific FcRH5:CD3 T-cell engaging antibody, in patients with relapsed/refractory multiple myeloma.Adam Cohen provides us with insights from pre-clinical data and explains the mechanism of action of BFCR4350A. He also describes the expression patterns of its target FcRH5, which make this drug less likely to have off-target effects and be specifically efficacious in patients with an amplification at the 1q21 locus. He also discusses the study design, criteria, and objectives of the phase I trial, including a step-up dosing regimen aimed to mitigate cytokine syndrome and neurotoxicity. Hosted on Acast. See acast.com/privacy for more information.

Multiple Myeloma Hub
Updates from the KarMMa trial

Multiple Myeloma Hub

Play Episode Listen Later Jun 18, 2020 7:13


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US. In this podcast, he discusses the recent updates from the KarMMa phase II trial (NCT03361748). in patients with relapsed/refractory multiple myeloma.Nikhil Munshi describes the mechanism of action of the idecabtagene vicleucel (ide-cel) BCMA targeting CAR T-cell therapy before detailing the study design. He then provides results from the 128 patients enrolled in the study, including and dose-response rates, overall response rates, complete response rates, and MRD negativity rates. He also describes the safety profile including cytokine release syndrome, neurotoxicity and cytopenias. These results demonstrate deep and durable responses for a heavily pre-treated patient population with relapsed/refractory multiple myeloma. Hosted on Acast. See acast.com/privacy for more information.

Multiple Myeloma Hub
Update from CARTITUDE-1 | What's new since ASH?

Multiple Myeloma Hub

Play Episode Listen Later Jun 8, 2020 5:56


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon Research Institute, Nashville, US. In this podcast, he discusses the latest updates from the CARTITUDE-1. This was a phase I/IIb study of JNJ-4528, a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR T)-cell therapy in patients with relapsed/refractory multiple myeloma.Jesus Berdeja begins by explaining the construct is different to other BCMA CAR T-cell constructs and then goes on to describe the study design, including patient characteristics and eligibility. He then describes the safety results from this study including the late onset of cytotoxic syndrome. He also discusses the overall response rate and measurable residual disease negativity. Hosted on Acast. See acast.com/privacy for more information.

nashville acast american society jnj bcma clinical oncology asco annual meeting
Multiple Myeloma Hub
Should we use KRd or VRd for patients with NDMM?

Multiple Myeloma Hub

Play Episode Listen Later Jun 4, 2020 7:12


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, Rochester, US. We asked: Should we use carfilzomib, lenalidomide, and dexamethasone (KRd) or bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma (NDMM)? In this podcast he describes the results of the ENDURANCE (E1A11) phase III trial.Shaji Kumar discusses the results of the primary endpoints: progression-free survival, and duration of therapy, as well as the secondary endpoints: MRD-negativity, overall survival, and toxicity. He also discusses quality of life metrics, including renal and neurotoxicity-related symptoms. As this study excluded high-risk patients, Shaji Kumar briefly describes the results of another trial (S1221) that enrolled a high-risk patient population to fully answer the question. Hosted on Acast. See acast.com/privacy for more information.

Multiple Myeloma Hub
Novel approaches in multiple myeloma: TAK-079

Multiple Myeloma Hub

Play Episode Listen Later Jun 4, 2020 5:46


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope, Duarte, US. In this podcast, she discussed the phase I data of TAK-079, a novel anti-CD38 monoclonal antibody, in a heavily pre-treated population of patients with multiple myeloma.She begins be describing the uniqueness of TAK-079 over other approved anti-CD38 antibodies and describes the mechanism of action. Amrita Krishnan then begins to discuss the promising safety and tolerability results including no infusion-related reactions and no significant lymphopenia or thrombocytopenia. Hosted on Acast. See acast.com/privacy for more information.

Multiple Myeloma Hub
What is the optimal treatment for bone lesions, including patients with renal insufficiency?

Multiple Myeloma Hub

Play Episode Listen Later Jun 3, 2020 7:21


During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massachusetts General Hospital, Boston, US. We asked: what is the optimal treatment for bone lesions, including patients with renal insufficiency?In this podcast, Elizabeth O'Donnell discusses how bone-directed therapy is an important component of multiple myeloma (MM) therapy. She describes the study which led to the FDA approval of denosumab, before describing results from the ongoing phase II, single-arm study of denosumab in patients with MM with real insufficiency (creatinine clearance < 30). She focuses on the safety profile and adverse events including neurotoxicities and hypocalcemia. Hosted on Acast. See acast.com/privacy for more information.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 17, 2019 70:43


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 17, 2019 70:39


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 17, 2019 70:43


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 17, 2019 70:39


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jul 17, 2019 70:43


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Professor Claire Harrison - Changing the Treatment Story in Myelofibrosis: New Science and More Choices for Challenging Cases in the JAK Inhibitor Era

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 17, 2019 70:39


Go online to PeerView.com/SCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence of JAK inhibitor therapy for the management of myelofibrosis has offered clinicians effective targeted therapy options that can be used in different patient populations to improve outcomes and ameliorate the debilitating symptoms of myelofibrosis. As additional JAK inhibitors near regulatory approval, several therapeutic questions have emerged, including those over the use of multiple JAK inhibitor options in patients failing prior targeted therapy or those who present with challenging clinical features at baseline, among others. The answers to these questions will likely define the future of risk-adapted therapy in myelofibrosis and clarify treatment protocols in an era of several JAK inhibitor options. In this activity, based on a recent live symposium held in Chicago, Illinois, during the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, experts in oncology and hematology explore the answers to these questions via a unique MasterClass and Case Forum format, designed to offer learners a window into the scientific evidence supporting new JAK inhibitor options in myelofibrosis, while also providing a case-centric illustration of how this science can be applied in daily care. This activity marries expert insight on practice-changing science with recommendations from the therapeutic “masters” and highlights how JAK inhibitor options are making a difference in patient outcomes across the myelofibrosis treatment continuum. Upon completion of this activity, participants should be better able to: Describe molecular and clinical features of myelofibrosis (MF) that are useful for diagnostic and prognostic assessment, Summarize recent efficacy and safety evidence on established and emerging JAK inhibitors and other targeted agents in the management of MF, Select individualized, risk-adapted treatment plans for patients with symptomatic or asymptomatic MF, including those failing prior JAK inhibitor therapy.